VivaVision Biotechnology, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From VivaVision Biotechnology, Inc.
In the private market, eight Chinese biotechs raised a combined $116m in deals backed by venture capital and private equity firms over the past few weeks.
Evopoint and Kaken also ring in the new year with multiple deals. Biocytogen licenses antibodies against a specified target derived from its RenMice platform technology to Hansoh Pharma.
- Other Names / Subsidiaries
- Visou Biotechnology
- Weimou Biotechnology Co, Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.